The pharmacokinetic profile, tolerability and efficacy of benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) were studied in dogs with mammary cancer. A three-level response surface pathway designed trial was performed on seven dogs. At each level BP-C1 was administered subcutaneously daily for 7 days followed by a 7-day rest period in a dose escalating manner. Adverse events according to VCOG-CTCAE, performance status and tumour progression were recorded. The pharmacokinetic profile followed a two-compartment model with rapid absorption, short distribution, and a slow elimination phase. The overall elimination half-life was 125 h. The maximum tolerated dose of BP-C1 was estimated to be above 0.46 mg kg −1 . A significant reduction in VCOG-CTCAE toxicity which correlated negatively with increasing dose was found. The dogs' general performance status remained unchanged. No decrease in total tumour burden was found, although temporary tumour reduction was seen in some target tumours.
Introduction
Mammary tumours are the most common neoplasm in unspayed female dogs, accounting for 50-70% of all tumours. 1 -4 Because almost half of these tumours are malignant, 5 with the potential to invade surrounding tissue and develop regional and distant metastases, mammary tumours represent a significant health problem in this subset of the dog population.
Surgical removal of tumours is still the main treatment option in canine mammary tumour cases, but based on the recognition that up to 50% of dogs with malignant mammary tumours (MMTs) are not cured by surgery alone, 6, 7 alternative systemic treatments to control the metastatic disease are needed to improve the life quality and survival in these dogs. Chemotherapy is commonly offered to women either with or at risk of metastatic breast cancer due to its proven ability to increase the women's disease-free period and rate of survival. 8 Hence, adjuvant chemotherapy is similarly recommended for dogs with mammary tumours with poor prognosis. 9 However, to date, no prospective randomized clinical trials have shown any clear benefits of adjuvant chemotherapy, such as 5-fluorouracil 10 and cyclophosphamide, 10 doxorubicin, 11 docetaxel, 11 or gemcitabine, 12 although there are some indications that such treatments may be beneficial. 10, 11, 13 This emphasizes the need for further studies of existing chemotherapy drugs, but also shows the importance of the development of novel anticancer agents and investigation of their antineoplastic efficacy in dogs.
An in vitro study of canine mammary tumour cells demonstrated that carboplatin, cisplatin and doxorubicin had an inhibitory effect on the DNA concentration 24-72 h after treatment. The measured 50% inhibitory concentration varied according to tumour cell type, and type of drug and dosage. 14 However, due to severe dose-dependent side effects, cancer treatment with the most common platinum drugs, cisplatin and carboplatin, to dogs and humans have limitations. Hence, there is an ongoing search for new anticancer drugs with fewer side effects. A novel platinum agent, benzene-polycarboxylic acids complex with cis-diammineplatinum (II) dichloride (manufacturer's code: BP-C1), is classified as an anti-cancer category 2 compound and is composed of a polymer complex of carbonic and oxicarbonic acids rich in carboxyl-groups which replace the chloride ions. In the treatment of dogs, the product's trade name is Immovet C8. Through reaction with platinum, a cis-configuration diamino-dicarboxilate complex is formed. These carboxyl groups, being a part of a complex organic compound, binds platinum more tightly than the chlorine ions, and are therefore thought to have a positive impact on toxicity of the compound compared to cisplatin and carboplatin. We know from as yet unpublished data that BP-C1 acts differently from cisplatin (Christina WY, 2008, personal communication), which is known to react with DNA by forming intra-strand and inter-strand crosslinks. 15, 16 An in vitro study of the effect of BP-C1 on the growth of human breast cancer cells, MCF7 and T47D, has shown that BP-C1 reduced the cell viability of human cancer cells by induction of apoptosis through activation of the extrinsic and the intrinsic apoptotic pathways. 17 Furthermore, the results from a recently performed dose-finding study in women suffering from metastatic breast cancer stage IV demonstrated good tolerability combined with a promising clinical effect. 18 BP-C1 can be administered both intramuscularly (IM) and subcutaneously (SC) and thus, given sufficient efficacy, it could be easily administered when treating cancer in dogs. Pharmacokinetic (PK) studies of a novel compound in the target species are important to determine optimal doses and predict side effects. To date, no studies of BP-C1 have been conducted in dogs. The PKs of a another platinum drug, dicycloplatin, which has a higher water solubility and higher stability compared to carboplatin, was recently reported from studies in rats and dogs, 19 but kinetic studies of anti-tumour platinum-based compounds in dogs is limited, and mainly restricted to single-dose studies in healthy animals. Thus, a multi-dose kinetic study of a population of target patients was considered beneficial for evaluating BP-C1 as a possible treatment alternative for dogs with mammary cancer. The purpose of the study was to predict the PK pattern, estimate the maximum tolerated dose (MTD) and to evaluate possible toxicity-and anti-tumour effect of BP-C1 in dogs with MMTs.
Material and methods

Study population
The study population consisted of privately owned female dogs with MMTs. Dogs with a body weight less than 5 kg, compromised liver or kidney functions, haematological status, or coagulation capacity were excluded. Pregnant or lactating dogs, dogs under systemic treatment with corticosteroids or other immunosuppressive drugs, and dogs participating in other clinical trials involving pharmaceuticals were also excluded from the study population.
Study sample and patient characteristics
The study sample consisted of seven dogs with metastatic or inoperable MMTs. Table 1 provides an Table 1 . Lung metastases were based on nodular soft tissue opacities at x-ray and computer tomography. In dog 3 it was also confirmed cytologically by FNA from one of the lung lesions. Later, at autopsy the lung lesions in all three dogs were histologically confirmed to be mammary metastases. The skin metastasis in dog 2 was confirmed histologically using punch biopsy to be metastases from anaplastic carcinoma. 
Study design and treatment
The study was performed as an open, non-randomized dose-escalating field study using a within-patient three-level response surface pathway (RSP) design. 20 The study was approved by the Norwegian Animal Research Authority and the Norwegian Medicines Agency and was conducted in the Faculty of Veterinary Medicine and Biosciences at Norwegian University of Life Sciences. A written informed consent was given by the owners before any study-related procedures were initiated. According to the RSP design the dose calculation used on each of the three design levels was based on the toxicity response obtained at the previous level and a k-adjustment factor estimated to ensure that the predefined dose window was covered. Every dog participated in all three design levels in which they received daily subcutaneous (SC) injections of BP-C1 for 7 days in each design level followed by a 7-day rest period. The predefined cumulative dose window of BP-C1 in dogs was 0.07-0.46 mg kg −1 body weight during the 7-day treatment period. One millilitre of Immovet C8 contained 0.5 mg of platinum-ammonium salts of benzene-polycarboxylic acids, including 0.05 mg of platinum (Pt). At design level 1, all dogs were given the mid-dose of the predefined cumulative dose window, which was equivalent to 0.26 mg BP-C1 kg −1 and represented a daily dose of 0.037 mg kg −1 over 7 days. If the dog showed none, mild or a moderate increase in toxicity from baseline, the dose for design level 2 was increased. If the increase in toxicity was severe or life threatening, the dose was reduced. The dose for design level 3 was determined in the same way, but based on the results obtained at the design level 2. The size of the escalation or reduction of the doses was hence determined by the design as illustrated in Table 2 .
Study procedure
During a screening phase of maximum 7 days prior to first treatment, owner consent was obtained, reproduction-and tumour history and the results from clinical examination and staging were recorded. Blood sampling for complete blood count, serum chemistry and urine analysis were performed in all dogs. Ultrasound examination of the abdomen and x-ray and CT of the thorax were performed to provide basal staging information in the dogs. Up to three of the largest tumour target lesions were selected and measured by calliper if accessible or built-in measuring equipment in the imaging instruments used (largest diameter in mm). The dogs received a daily SC injection of BP-C1 for 7 days. During the first design level extra blood samples for the PK study was collected after each injection before the dog was returned to the owner. Repeated physical examinations as well as new measures of tumour lesions, restaging and resampling of blood for new haematologicand serum chemistry profile were performed at the start (day 1) and 2 days after the last injection (day 9) in each design level, as well as seven days (day 14) after the last injection in the third design level. However the date for imaging could be shifted one day back or forward if scheduled on a holiday. For restaging, the most relevant imaging methods were repeated in order to describe and follow the development of the target lesions. In addition, any new tumour lesions were recorded. Fine-needle aspirates or tissue biopsies were used if needed in order to monitor tumour progression. Adverse events (AE) were monitored and recorded from the 
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a The number in brackets shows the cumulative doses at each design level (treatment dose level) by using the cumulative dose of m = 0.26 mg kg −1 body weight at the first level. k represents an adjustment factor constant.
time of the first injection of BP-C1 to 7 days after the last injection at design level 3.
Evaluation of the PK profile
Single-dose study
Two days before start of treatment in design level 1, each of the included dogs was given a single SC injection of 0.037 mg BP-C1 kg −1 . Blood was sampled 10, 20, 30, 40, 45 and 60 min and 6, 12, 24 and 48 h after injection for the PK study.
Cumulative-dose study
The blood sample collected 48 h after the initial injection in the single-dose study was taken before the first injection in the cumulative study. The dogs were given one SC injection of 0.037 mg BP-C1 kg −1 daily for 7 days at design level 1, representing a cumulative dose of 0.26 mg kg −1 . During the first 6 days, blood samples were collected 30 min after each injection. On the seventh day of treatment at design level 1, blood samples were again sampled 10, 20, 30, 40, 45 and 60 min and 6, 12, 24 and 48 h after injection. The level of Pt in the blood was determined at the National Institute of Occupational Health in Oslo, Norway. The samples were prepared by adding 2 mL of 65% ultrapure nitric acid and 100 μL of an internal standard solution containing 1 μg mL −1 of thallium to 1 mL of EDTA whole blood in a polypropylene tube. After heating to 90 ∘ C for 90 min and cooling to room temperature, the samples were diluted to 14 mL with deionized water. The analysis was performed using inductively coupled plasma-sector field mass spectrometry (ICP-SFMS). The Pt concentration was quantified using a standard curve of different BP-C1 concentrations in EDTA whole blood. The detection limit of the method for Pt concentration was 0.05 μg L −1 . The Pt concentrations, not the BP-C1 concentrations, were used in the PK modelling.
PK variables
Variables related to the PKs were maximum Pt concentration in blood (C max ), time from injection to C max (T max ), distribution half-life (T1 ∕2 ), elimination half-life (T1 ∕2 ), distribution volume (V d ), total body clearance (Cl T ), the area under the concentration versus time-curve until infinity (AUC 0-∞ ) in the single-dose PK profile, and maximum steady-state concentration (C ss ) and the time passed until 90% of steady state (C ss90 ) would be achieved (T ss90 ) in the multi-dose PK profile.
Evaluation of toxicity
The tolerability of the treatment was evaluated and recorded by the same veterinarian 2 days after the last injection at all three design levels using the Veterinary Co-operative Oncology Group's common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats version 1.0. 21 These criteria consist of 168 clinical and laboratory items divided into 21 categories graded as: 1 = none or mild, 2 = moderate, 3 = severe, 4 = life threatening and 5 = death related to AE. Any unfavourable or unintended clinical or laboratory findings were recorded as AE and scored accordingly on the scale 1-5 for each event.
AEs reported by the owners were also included. For each dog the sum of the total toxicity score (Sum VCOG-CTCAE) and the highest grade of toxicity scored on single event (Max VCOG-CTCAE) were recorded. In addition, the dogs' performance status was measured at the same time points using the Modified Karnofsky Performance Score Criteria (MKPS). 22
Toxicity variables
Max VCOG-CTCAE was used as the main variable for toxicity together with the mean of the Sum VCOG-CTCAE. The change in Max VCOG-CTCAE from screening to 2 days post-treatment at each design level was the variable determining the dose at next design level. Additionally, a single-case pattern analysis for each individual dog was performed by using the multi-crossover (MCO) model 23 -25 with sum VCOG-CTCAE of target tumours as outcome variables. The MCO score was defined as the number of times the situation at the end of each treatment period was better compared to that of the rest period before and after, thus displaying the pattern of toxicity and resulting in a MCO score ranging from 0 to 6 in this study. MCO score ≥ 4 classifies responders. The MCO Efficacy Index was defined as the mean of the six recorded sum VCOG-CTCAE differences expressing the degree of difference in the toxicity score during the periods of treatment compared to periods of rest. MTD was defined as the highest cumulative dose causing severe or life-threatening toxicity with a probability less than or equal to one-third.
Evaluation of clinical efficacy
In order to evaluate the clinical efficacy of BP-C1, tumour burden and the dogs' performance status were recorded. The variables for tumour response included number of metastatic lesions and the sum of the longest diameter in the target lesions. In addition, the tumour response 7 days after the last treatment in the study was categorized relative to baseline measurements as complete response (CR, 100% disappearance of all lesions), partial response (PR, ≥50% decrease), stable disease (SD, no change or <50% decrease), or progressive disease (PD, ≥25% increase). 26 Both target tumours, non-target tumours and occurrence of new lesions were included in this classification. MKPS score was used as response variable for effect of BP-C1 on general performance status.
PK modelling
The software used for PK modelling was WinNonlin 5.2 (Pharsight Corporation, Cary, NC, USA). The PK data for the first dose (0-48 h) were first modelled on basis of the average concentrations of Pt at each time-point. Non-linear modelling with bolus input, first order absorption and first order elimination in either a one-compartmental model or a two-compartmental model were tested. Both one-and two-compartment models were tested to identify the best fitting of the data. The single-dose and multi-dose data were modelled for each animal, and descriptive statistics for the parameters were calculated.
Statistical analysis
Assumed continuously distributed variables were expressed by mean values with 95% confidence intervals. 27 Standard deviation (sd) was used for expression of the dispersion. In cases of unimodal skewed distribution, the data were logarithmically transformed before the analysis was performed. The results were retransformed for presentation. Isotonic regression was used to model MTD estimation. 28 -31
All comparisons were performed two-tailed and differences were considered statistically significant if the P value was less than or equal to 5%. Changes within groups with regard to assumed continuously distributed variables were performed using Analysis of Variance. 32 Categorized and discontinuously distributed variables were expressed in contingency tables and analysed using Contingency Table  Analysis .
Results
PK profile
The single-dose PK data fitted well with a two-compartment open model with bolus input and first order elimination. The best fit was obtained for average Pt values in plasma (R 2 = 0.998), and all concentration versus time data for individual animals could be fitted to the model.
The modelling of the single-dose data demonstrated that the compound was rapidly absorbed after SC injection, with mean C max reached after 24 min (sd: 10) (Fig. 1A) . It was rapidly distributed from the central compartment to peripheral tissues with a mean distribution half-life, T1 ∕2 , of 35 min (sd: 24) ( Table 3 ). The distribution to the tissues was extensive, with a distribution volume (corrected for bioavailability, F) for the central compartment (V d 1/F) of 0.79 L kg −1 (sd: 0.33) and a corresponding volume for the peripheral compartment (V d 2/F) of 1.85 L kg −1 (sd: 0.48). Thus, the peripheral compartment was estimated to be more than twice as big as the central compartment. The Pt compound was rather slowly excreted (Fig. 1B) . The total body clearance (Cl T /F) was 0.026 L h kg −1 (sd: 0.006). The uncorrected distribution volumes and clearance rates are expected to be very close to these values, as the bioavailablity after SC injection is expected to be close to 100%. The elimination half-life, T1 ∕2 , was 73.5 h (sd: 15.6) or 3 days, and the area under the concentration-versus-time curve (AUC 0-∞ ) was 147 h μg L −1 (sd: 29) .
When all data from the multi-dose part of the study were included in the model, it became evident that the overall elimination rate was slower (Fig. 1C) . This is reflected by a total body clearance Cl T /F of 0.018 (sd = 0.004) L h kg −1 and an elimination half-life, T1 ∕2 , of 125 h (sd: 35) or 5.2 days (Table 3 ; Fig. 1C ). Due to the slow excretion, the substance was not completely eliminated from the body at 24 h after injection (Fig. 1C) . The next dose therefore lead to increased blood concentration until a steady state concentration was reached. Assuming daily injections with the same dose, 90% of the steady state concentration estimated to11 μg L −1 was predicted to be reached after 17 injections.
Toxicity
At design level 1 the Max VCOG-CTCAE toxicity score was found unchanged in four dogs and increased with one score in three dogs. All dogs were thus given the maximal dose of 0.39 mg kg −1 at design level 2 (Fig. 2) . During design level 2, the maximum toxicity score decreased with two scores in one dog and remained unchanged in six dogs. Consequently, all dogs were given the absolute maximal cumulative dose of 0.46 mg kg −1 in design level 3. Max VCOG-CTCAE toxicity score was found unchanged in all seven dogs 2 days after the last injection at design level 3. Life-threatening AEs were not seen, even though all dogs reached the highest cumulative dose. Based on these results, the MTD of BP-C1 was estimated to be above 0.46 mg kg −1 .
During design level 1 (days 1-9), a non-significant reduction in the mean value of all the dogs Sum VCOG-CTCAE toxicity score from 12.0 (95% CI: 3.8-20.2) to 11.0 (95% CI: 6.6-15.4) was detected (Table 4 ; Fig. 3 ). At design level 2, the mean Sum VCOG-CTCAE toxicity score was also non-significantly reduced, from 11.1 (95% CI: 5.6-16.7) to 9.0 (95% CI: 4.2-13.8). During design level 3 with maximal dose, the mean sum toxicity score was found significantly reduced from 9.6 (95% CI: 5.5-16.7) to 8.0 (95% CI: 3.3-12.7) (P = 0.01). The mean sum toxicity score increased again significantly (P = 0.03) to 9.1 (95% CI: 3.9-14.4) from 2 to 7 days after the last injection. Overall, the Sum VCOG-CTCAE toxicity score was significantly reduced (P < 0.05) from screening to the last follow-up in the study. In the single-case analysis, three of the seven dogs were classified as MCO responders based on VCOG-CTCAE toxicity pattern (Table 4 ). A total of 124 AEs were reported during the study. Of those, only nine were classified as 'probably' related to the trial treatment, of which all were described as 'Mild'. The AEs were described as decreased Fe (n = 1), hyperpigmentation (n = 1), increased CK (n = 1), low APTT (n = 1), motor muscle weakness (n = 1), slightly elevated protrombine time (n = 1), pruritus (n = 1), and vomiting/ nausea (n = 2). Regarding the MKPS, only minor changes were detected during the three design levels and the performance status 2 days after the last injection at design level 3 was comparable to that before the initial injection.
Clinical efficacy
Based on the change in the sum of the tumour diameter in the target lesions and the development of new lesions in the 43 days from the time of screening until 7 days after the last injection at design level 3, three of the dogs were classified as having SD and four as having PD. However, a temporary decrease of tumour size was seen in some of the target lesions during the study period. (Table 5 )
Laboratory analysis
Haemoglobin concentration, red blood cell count, and the haematocrit increased during design levels 1 and 3. From start at design level 1 to 7 days after the last injection at design level 3 the haemoglobin concentration, red blood cell count, and the haematocrit increased. During design levels 2 and 3 both mean cell volume and eosinophil leucocytes increased. Albumin was below normal range for six of the seven dogs before the start of treatment. During design level 1 the albumin increased significantly (P < 0.01) and was normalized in all seven dogs. During the following two design levels, the albumin level remained almost unchanged. From the start of the treatment at design level 1 to 7 days after the last injection at design level 3, the bilirubin concentration was decreased.
Discussion
The study was designed as a phase 1 study to evaluate the PK of Pt and to estimate the MTD and the development of toxicity when repeatedly administrating BP-C1 in a dose escalating manner to dogs diagnosed with MMT. The PK of BP-C1 followed a two-compartmental model with a fast distribution phase and a slow elimination phase. After SC injection the absorption of the compound -measured as free elementary Pt in blood -was rapid, with maximum blood concentrations (C max ) reached within half an hour. When comparing the PK variables of BP-C1 in the study with the results reported from a study of dicycloplatin in dogs, 19 the single dose of Pt used in our study was less than 1/500 of the Pt dose used by Zhao et al. (2012) (1.9 mg Pt kg −1 ). As a consequence, the C max and AUC 0-∞ found in our study were correspondingly lower. Nevertheless, the elimination half-life T1 ∕2 was long for both compounds in dogs: 4.5 days for dicycloplatin 19 and 5.2 for BP-C1. BP-C1 was rapidly distributed from the central compartment to peripheral tissues, and the peripheral compartment was estimated to be approximately twice as big as the central compartment. The probable explanation for the long elimination half-life is a slow redistribution from tissue back to plasma. Given the slow excretion, the next dose given after 24 h would lead to cumulative blood concentration until a steady state concentration is reached. The elimination half-life of other platinum compounds as cisplatin and carboplatin for dogs is much shorter than from BP-C1 and dicycloplatin. 33 The slow elimination rate indicates that animals excrete the compound for a considerable period of time, which should be considered if the product is used on an out-patient basis.
BP-C1 was found to be well tolerated, with few and mainly mild adverse effects. No severe or life-threatening AEs were observed even on the highest dose in the predefined dose window. The toxicity according to the VCOG-CTCAE criteria was significantly reduced during the BP-C1 treatment and the degree of toxicity was negatively correlated with increasing dose. This finding is in accordance with the results from a similar study of human breast cancer. 18 The toxicity recorded at screening is mainly caused by the disease itself, while at the end of treatment the toxicity is influenced also by the compound given to the participant. The addition of an assumed toxic drug is thus expected to increase the toxicity. The fact that the toxicity was negatively correlated with the dose also indicates that most probably the true value of MTD is above the upper level of the dose window. Even at the highest dose used in the study, no negative gastrointestinal or haematological effects were recorded. Furthermore, BP-C1 seems to be able to correct hypoalbuminaemia in dogs. This finding is in accordance with those in the comparable human study. 18 A significant favourable effect of BP-C1 on the overall tumour progression when considering both target lesions and new metastases could not be demonstrated in the seven dogs from the time of screening until one week after last treatment, as three dogs were classified as having SD and four as having a PD, and the sum of tumour diameters increased significantly from screening until the last follow-up in the study. However, some temporary tumour reduction was seen in a couple of dogs. As the last tumour size measurements are performed only 7 days after the last day of treatment, more delayed antineoplastic effect cannot be excluded. Further, as the maximum tolerated dose was not reached during the treatment period, it can be assumed that the dose could have been set higher and the treatment regime could have been more intense, possibly leading to better anti-tumour efficacy. However, whether the extended elimination time of BP-C1 represents a long-term hazard to the environment and the care giver is not known and need further evaluation.
To date, no reports have been found in the literature showing that canine MMT could successfully be treated by chemotherapy alone. Doxorubicin has been used as adjuvant therapy after surgery in malignant mammary carcinomas with varying success. The effect of chemotherapy on the rate of metastasis, recurrence after surgery, and survival, has not been determined in well-designed prospective studies. Platinum-based drugs have been shown to have an inhibitory effect on canine mammary tumour cells grown in vitro. 14 In the aforementioned study, carboplatin and cisplatin were compared with doxorubicin, and the 50% inhibitory effect was determined. The in vitro inhibitory concentration of carboplatin was relevant to the recommended clinical doses that are used in chemotherapy in dogs. First-generation platinum compounds such as cisplatin show dose-limiting toxicities, and other compounds, such as carboplatin, have been developed with improved toxicity profiles. Carboplatin is used routinely as a chemotherapy drug to treat various cancers in dogs, but is not established as an adjuvant therapy for treating mammary tumours.
Severe myelo-suppression also develops after carboplatin and the drug is unstable in an aqueous solution. 19 New platinum compounds such as dicycloplatin have shown promising tumour-inhibiting effects in vitro. 34 BP-C1 is a new compound, combining benzene-poly-carboxylic acid and Pt in a very low dose, giving a very low concentration of free platinum in blood compared to levels of cisplatin and carboplatin normally seen in blood after treatment. However, the mechanism of action (MoA) of this new complex differs from the MoA of BP-Cx-1 and platinum separately; it is the combination that is responsible for the cell-killing effect of BP-C1 seen in vitro. MoA probably involves factors associated with DNA damage and repair, and with a membranotropic effect. 17 Apoptotic pathways including preapoptotic genes are probably also involved. 35 To date, there have been no published in vitro studies of canine mammary tumour cells showing that BP-C1 induces cell tumour regression or tumour death at the doses achieved in our study. However, in an in vitro study of human mammary cancer cells, a 50% cell growth inhibition was demonstrated when using a concentration more than 1000 times higher than the accumulated C max of Pt in our study. 17 It is unclear whether an in vivo therapeutic effect could be achieved for mammary cancers in dogs with the doses used in our study, as the effect of BP-C1 probably depends on another mechanism than caused by Pt alone. However, the low toxicity and similar PK as dicycloplatin make BP-C1 a promising potential adjuvant antineoplastic therapeutic compound for the treatment of dogs, given therapeutic effect can be reached.
The present study is the first attempt to define MTD and treatment regime for BP-C1 in dogs with MMT. It was designed as a within-patient RSP trial with three design levels. In order to obtain the same power as in a traditional parallel-group design, at least seven dogs in each of three groups has to be included. 36 It is shown in the development of the RSP-design that this design reduces the sample size from 36 to 15 without loss of information. 20 Consequently, the seven patients in this within-patient RSP study will have a power above the one obtained in a traditional parallel-group design with 16 patients in each of three groups.
The fact that the BP-C1 significantly decreased the VCOG-CTCAE toxicity could give it a role as a palliative anti-cancer drug for use either alone or in an adjuvant setting.
Conclusion
The PK pattern of BP-C1 follows a twocompartment model with a short first compartment and a very slow second compartment. The drug was well tolerated, with a significant reduction in toxicity. The sum VCOG-CTCAE was negatively correlated with increasing dose. By using the predefined cumulative dose window and treatment regime, no overall significant anti-tumour efficacy was observed. However, some temporary individual tumour reduction was observed during treatment periods, so it is possible that increased dose and more intense treatment regime could improve the anti-tumour efficacy.
